Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00003868
Status:
COMPLETED
Last Update Posted:
2010-08-24
First Post:
1999-11-01
Brief Title:
Radiolabeled Monoclonal Antibody Cyclophosphamide and Total Body Irradiation Followed By Donor Stem Cell Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia
Sponsor:
Fred Hutchinson Cancer Center
Organization:
Fred Hutchinson Cancer Center
Study Overview
Official Title:
Radiolabeled BC8 Anti-CD45 Antibody Combined With Cyclophosphamide and Total Body Irradiation Followed by HLA-matched Related or Unrelated Stem Cell Transplantation as Treatment for Advanced Acute Myeloid Leukemia and Myelodysplastic Syndrome
Status:
COMPLETED
Status Verified Date:
2010-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Radiolabeled monoclonal antibodies can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die Radiation therapy uses high-energy x-rays to damage cancer cells Donor stem cell transplantation may be able to replace immune cells that were destroyed by radiolabeled monoclonal antibody therapy chemotherapy and radiation therapy
PURPOSE Phase II trial to study the effectiveness of combining radiolabeled monoclonal antibody with cyclophosphamide and total-body irradiation followed by donor stem cell transplantation in treating patients who have advanced acute myeloid leukemia
PURPOSE Phase II trial to study the effectiveness of combining radiolabeled monoclonal antibody with cyclophosphamide and total-body irradiation followed by donor stem cell transplantation in treating patients who have advanced acute myeloid leukemia
Detailed Description:
OBJECTIVES
Determine the efficacy in terms of overall survival and disease-free survival and toxicity of cyclophosphamide and total body irradiation in patients with acute myeloid leukemia beyond first remission receiving HLA-matched related or unrelated hematopoietic stem cell transplantation
Determine the maximum tolerated dose MTD of iodine I 131 monoclonal antibody BC8 I131 MOAB BC8 in these patients
Estimate the MTD of radiation delivered by I 131 MOAB BC8 to marrow of these patients and assess the effects on growth of marrow stroma in vitro
OUTLINE This is radiation dose-escalation study Patients are stratified according to available donor related vs unrelated
Patients receive a biodistribution dose of iodine I 131 monoclonal antibody BC8 I131 MOAB BC8 IV then a therapeutic dose of I131 MOAB BC8 IV 6-14 days later day -12 Patients undergo total body irradiation twice daily on days -6 to -4 Patients receive cyclophosphamide IV on days -3 and -2 Bone marrow cells or peripheral blood stem cells are infused on day 0
Patients with CNS leukemic involvement receive intrathecal methotrexate twice before the transplantation then every other week for 8 weeks beginning on day 32 These patients also receive cranial irradiation beginning on day 32
Cohorts of 4 patients each receive escalating doses of iodine I 131 attached to a standard dose of monoclonal antibody BC8 until the maximum tolerated dose MTD is determined The MTD is defined as the radiation dose preceding that at which 2 of up to 6 patients experience graft failure
Patients are followed at 6 9 and 12 months every 6 months for 1 year and then annually thereafter
PROJECTED ACCRUAL A total of 40 patients 20 per stratum will be accrued for this study within 4 years
Determine the efficacy in terms of overall survival and disease-free survival and toxicity of cyclophosphamide and total body irradiation in patients with acute myeloid leukemia beyond first remission receiving HLA-matched related or unrelated hematopoietic stem cell transplantation
Determine the maximum tolerated dose MTD of iodine I 131 monoclonal antibody BC8 I131 MOAB BC8 in these patients
Estimate the MTD of radiation delivered by I 131 MOAB BC8 to marrow of these patients and assess the effects on growth of marrow stroma in vitro
OUTLINE This is radiation dose-escalation study Patients are stratified according to available donor related vs unrelated
Patients receive a biodistribution dose of iodine I 131 monoclonal antibody BC8 I131 MOAB BC8 IV then a therapeutic dose of I131 MOAB BC8 IV 6-14 days later day -12 Patients undergo total body irradiation twice daily on days -6 to -4 Patients receive cyclophosphamide IV on days -3 and -2 Bone marrow cells or peripheral blood stem cells are infused on day 0
Patients with CNS leukemic involvement receive intrathecal methotrexate twice before the transplantation then every other week for 8 weeks beginning on day 32 These patients also receive cranial irradiation beginning on day 32
Cohorts of 4 patients each receive escalating doses of iodine I 131 attached to a standard dose of monoclonal antibody BC8 until the maximum tolerated dose MTD is determined The MTD is defined as the radiation dose preceding that at which 2 of up to 6 patients experience graft failure
Patients are followed at 6 9 and 12 months every 6 months for 1 year and then annually thereafter
PROJECTED ACCRUAL A total of 40 patients 20 per stratum will be accrued for this study within 4 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CDR0000067032 | REGISTRY | PDQ | None |
| FHCRC-129700 | None | None | None |
| NCI-H99-0028 | None | None | None |